Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ERASE-CRC
2024-515152-20-00Phase 2Suspended
- Sponsor
- Gruppo Oncologico Nord Ovest
- Start
- Nov 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of trifluridine + tipiracil, FOLFIRINOX, trastuzumab and tucatinib in colon adenocarcinoma and rectal adenocarcinoma (4 arms), sponsored by Gruppo Oncologico Nord Ovest. Primary endpoints: ct-DNA clearance rate (Part 1), ct-DNA clearance rate (Target-driven Part 1) and 1 more. Started Nov 2024; status: suspended.
02
Drugs
03
Conditions
colon adenocarcinomarectal adenocarcinoma
Beyond the preview
Go deeper on 2024-515152-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515152-20-00.